Cover Image
市場調查報告書

Zymenex A/S- 產品臨床實驗回顧

Zymenex A/S - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 203751
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Zymenex A/S- 產品臨床實驗回顧 Zymenex A/S - Product Pipeline Review - 2014
出版日期: 2014年05月30日 內容資訊: 英文 30 Pages
簡介

Zymenex A/S 未來有希望治療藥物包括中樞神經、胃腸、感染症、代謝異常、遺傳性疾病等, 對應市場需求、著重於開發未來對患者而言具有優勢的混合物, 與製藥公司合作希望創造出新的價值。

本報告針對Zymenex A/S治療藥開發臨床實驗現況與各開發階段比較分析、提供藥劑標的、作用程序、投藥過程、分子種類分類治療藥評價、最新企業新聞發表、後期階段與中止方案相關資料。

Zymenex A/S基本情報

Zymenex A/S概要

  • 主要情報
  • 企業情報

Zymenex A/S:R&D概要

  • 主要治療範圍

Zymenex A/S:臨床實驗回顧

  • 開發階段分類臨床實驗產品
  • 單劑產品

Zymenex A/S:臨床實驗產品概況

  • 最終階段臨床實驗產品
    • 第III期產品/併用療法模式
  • 測試階段臨床實驗產品
    • 第II期產品/併用療法模式
  • 初期階段臨床實驗產品
    • 前臨床階段產品/併用療法模式
    • 創藥中產品/併用療法模式

Zymenex A/S:藥劑檔案

  • Recombinant Human Alpha-Mannosidase
  • ACE-527
  • ACE-920
  • Galaczym
  • ZA-011

Zymenex A/S:臨床實驗分析

  • 標的分類
  • 投藥通路分類
  • 分子種類分類
  • 作用排序分類

Zymenex A/S:最近臨床實驗動向

Zymenex A/S:暫停的方案

Zymenex A/S:開發中止臨床實驗產品

  • 開發中止的臨床實驗產品檔案
  • Porphozym

Zymenex A/S:總公司與子公司所在地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04927CDB

Global Markets Direct's, 'Zymenex A/S - Product Pipeline Review - 2014', provides an overview of the Zymenex A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Zymenex A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Zymenex A/S including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Zymenex A/S's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Zymenex A/S's pipeline products

Reasons to buy

  • Evaluate Zymenex A/S's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Zymenex A/S in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Zymenex A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Zymenex A/S and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zymenex A/S
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Zymenex A/S and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Zymenex A/S Snapshot
    • Zymenex A/S Overview
    • Key Information
    • Key Facts
  • Zymenex A/S - Research and Development Overview
    • Key Therapeutic Areas
  • Zymenex A/S - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Zymenex A/S - Pipeline Products Glance
    • Zymenex A/S - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Zymenex A/S - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Zymenex A/S - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Zymenex A/S - Drug Profiles
    • Recombinant Human Alpha-Mannosidase
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACE-527
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACE-920
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Galaczym
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZA-011
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Zymenex A/S - Pipeline Analysis
    • Zymenex A/S - Pipeline Products by Target
    • Zymenex A/S - Pipeline Products by Route of Administration
    • Zymenex A/S - Pipeline Products by Molecule Type
    • Zymenex A/S - Pipeline Products by Mechanism of Action
  • Zymenex A/S - Recent Pipeline Updates
  • Zymenex A/S - Dormant Projects
  • Zymenex A/S - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • Porphozym
  • Zymenex A/S - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Zymenex A/S, Key Information
  • Zymenex A/S, Key Facts
  • Zymenex A/S - Pipeline by Indication, 2014
  • Zymenex A/S - Pipeline by Stage of Development, 2014
  • Zymenex A/S - Monotherapy Products in Pipeline, 2014
  • Zymenex A/S - Phase III, 2014
  • Zymenex A/S - Phase II, 2014
  • Zymenex A/S - Preclinical, 2014
  • Zymenex A/S - Discovery, 2014
  • Zymenex A/S - Pipeline by Target, 2014
  • Zymenex A/S - Pipeline by Route of Administration, 2014
  • Zymenex A/S - Pipeline by Molecule Type, 2014
  • Zymenex A/S - Pipeline Products by Mechanism of Action, 2014
  • Zymenex A/S - Recent Pipeline Updates, 2014
  • Zymenex A/S - Dormant Developmental Projects,2014
  • Zymenex A/S - Discontinued Pipeline Products, 2014
  • Zymenex A/S, Other Locations

List of Figures

  • Zymenex A/S - Pipeline by Top 10 Indication, 2014
  • Zymenex A/S - Pipeline by Stage of Development, 2014
  • Zymenex A/S - Monotherapy Products in Pipeline, 2014
  • Zymenex A/S - Pipeline by Top 10 Target, 2014
  • Zymenex A/S - Pipeline by Top 10 Route of Administration, 2014
  • Zymenex A/S - Pipeline by Top 10 Molecule Type, 2014
Back to Top